RCMNY
KNSA icon

Rubric Capital Management (New York)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Rubric Capital Management (New York)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181M Buy
3,750,000
+421,347
+13% +$18.7M 1.91% 13
2025
Q4 		$137M Sell
3,328,653
-671,347
-17% -$26.9M 1.64% 16
2025
Q3 		$155M Buy
4,000,000
+90,194
+2% +$2.93M 1.75% 13
2025
Q2 		$108M Buy
3,909,806
+526,567
+16% +$13.4M 1.63% 16
2025
Q1 		$75.1M Buy
3,383,239
+764,136
+29% +$15.7M 1.35% 22
2024
Q4 		$51.8M Buy
2,619,103
+200,000
+8% +$4.56M 0.66% 31
2024
Q3 		$60.5M Hold
2,419,103
– – 0.99% 26
2024
Q2 		$45.2M Buy
2,419,103
+223,094
+10% +$4.18M 1.18% 35
2024
Q1 		$43.3M Sell
2,196,009
-711,492
-24% -$13.9M 1.28% 29
2023
Q4 		$51M Sell
2,907,501
-169,948
-6% -$2.79M 1.06% 22
2023
Q3 		$53.5M Sell
3,077,449
-300,715
-9% -$5.07M 2.01% 16
2023
Q2 		$47.6M Buy
3,378,164
+602,528
+22% +$8.06M 2.03% 20
2023
Q1 		$29.9M Buy
2,775,636
+1,206,133
+77% +$15.9M 0.77% 32
2022
Q4 		$23.5M Buy
1,569,503
+123,396
+9% +$1.8M 1.03% 34
2022
Q3 		$18.6M Buy
1,446,107
+922,579
+176% +$10.5M 0.94% 35
2022
Q2 		$5.07M Buy
+523,528
New +$4.88M 0.27% 60
2021
Q4 		– Sell
-153,618
Closed -$1.75M – 76
2021
Q3 		$1.75M Buy
+153,618
New +$2M 0.05% 57

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rubric Capital Management (New York)'s KNSA Position: Q1 2026 in Review

Rubric Capital Management (New York) increased its Kiniksa Pharmaceuticals (KNSA) stake by 13% in Q1 2026, buying an estimated $18.7M and bringing the position to 3,750,000 shares worth $181M. The position accounts for 1.91% of the portfolio, ranked #13.

Rubric Capital Management (New York) first reported a position in KNSA in Q3 2021 and has held it in 17 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Rubric Capital Management (New York) held 3,750,000 shares of Kiniksa Pharmaceuticals worth $181M as of Q1 2026.
  • Rubric Capital Management (New York) bought 421,347 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $18.7M.
  • Kiniksa Pharmaceuticals made up 1.91% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #13 holding.
  • Rubric Capital Management (New York) first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.